Owen A. O’Connor

20.7k total citations · 8 hit papers
334 papers, 13.3k citations indexed

About

Owen A. O’Connor is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Owen A. O’Connor has authored 334 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 190 papers in Pathology and Forensic Medicine, 129 papers in Molecular Biology and 122 papers in Oncology. Recurrent topics in Owen A. O’Connor's work include Lymphoma Diagnosis and Treatment (187 papers), Chronic Lymphocytic Leukemia Research (97 papers) and T-cell and Retrovirus Studies (60 papers). Owen A. O’Connor is often cited by papers focused on Lymphoma Diagnosis and Treatment (187 papers), Chronic Lymphocytic Leukemia Research (97 papers) and T-cell and Retrovirus Studies (60 papers). Owen A. O’Connor collaborates with scholars based in United States, Italy and Canada. Owen A. O’Connor's co-authors include Paul A. Marks, Jasmine Zain, Andrew D. Zelenetz, Steven M. Horwitz, William Kevin Kelly, Craig H. Moskowitz, Carol S. Portlock, Mark Heaney, Enrica Marchi and L. Y. Young and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Owen A. O’Connor

325 papers receiving 13.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

2005 739 citations William Kevin Kelly, Owen A. O’Connor et al. Journal of Clinical Oncology profile →
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

2010 663 citations Owen A. O’Connor, Ann S. LaCasce et al. profile →
Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

2002 586 citations Robert Z. Orlowski, Owen A. O’Connor et al. Journal of Clinical Oncology profile →
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

2006 553 citations Sagar Lonial, Owen A. O’Connor et al. Journal of Clinical Oncology profile →
Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model

2019 532 citations Owen A. O’Connor et al. profile →
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

2003 525 citations Victoria M. Richon, Owen A. O’Connor et al. profile →
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

2011 439 citations Owen A. O’Connor, Barbara Pro et al. Journal of Clinical Oncology profile →
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

2015 386 citations Owen A. O’Connor, Steven M. Horwitz et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Owen A. O’Connor

Since Specialization

Citations

This map shows the geographic impact of Owen A. O’Connor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Owen A. O’Connor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Owen A. O’Connor more than expected).

Fields of papers citing papers by Owen A. O’Connor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Owen A. O’Connor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Owen A. O’Connor. The network helps show where Owen A. O’Connor may publish in the future.

Co-authorship network of co-authors of Owen A. O’Connor

This figure shows the co-authorship network connecting the top 25 collaborators of Owen A. O’Connor. A scholar is included among the top collaborators of Owen A. O’Connor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Owen A. O’Connor. Owen A. O’Connor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) 2019 ·Blood ·Ahmed Sawas, Helen Ma, Andrei R. Shustov, (unknown), Gajanan Bhat, Mark Acosta, Steven M. Horwitz, Owen A. O’Connor	5
2	A phase 1/2 trial of ublituximab, a novel anti‐ CD 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab 2017 ·British Journal of Haematology ·Ahmed Sawas, Charles M. Farber, Marshall T. Schreeder, (unknown), Daruka Mahadevan, Changchun Deng, Jennifer E. Amengual, Petros Nikolinakos, Jill Kolesar, John G. Kuhn, Peter Sportelli, Hari P. Miskin, Owen A. O’Connor	61
3	A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma 2017 ·Blood ·Jennifer E. Amengual, (unknown), Jennifer Kimberly Lue, Ahmed Sawas, Changchun Deng, (unknown), (unknown), (unknown), Aishling M. Rada, (unknown), Codruța Chiuzan, Matko Kalac, Enrica Marchi, Lorenzo Falchi, (unknown), Lawrence Schwartz, Serge Cremers, Owen A. O’Connor	91
4	Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib 2016 ·Clinical Cancer Research ·Jennifer E. Amengual, Sathyen A. Prabhu, Maximilian Lombardo, Kelly Zullo, Paul Johannet, (unknown), Luigi Scotto, (unknown), (unknown), Jimmy Duong, Renu Nandakumar, Serge Cremers, Akanksha Verma, Olivier Elemento, Owen A. O’Connor	24
5	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study breakdown → 2015 ·Journal of Clinical Oncology ·Owen A. O’Connor, Steven M. Horwitz, Tamás Masszi, Achiel Van Hoof, Peter de Nully Brown, Jeanette K. Doorduijn, Georg Heß, Wojciech Jurczak, Poul Knoblauch, Shanta Chawla, Gajanan Bhat, Mi Rim Choi, Jan Walewski, Kerry J. Savage, Francine M. Foss, Lee F. Allen, Andrei R. Shustov	386
6	Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma 2015 ·Clinical Cancer Research ·Salvia Jain, (unknown), Kelly Zullo, Luigi Scotto, Carmine F. Palermo, Stephen A. Sastra, Kenneth P. Olive, Serge Cremers, Tiffany Thomas, (unknown), Yuan Zhang, Govind Bhagat, Jennifer E. Amengual, Changchun Deng, Charles Karan, Ronald Realubit, Susan E. Bates, Owen A. O’Connor	49
7	Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma 2015 ·Clinical Cancer Research ·Jatin J. Shah, Andrzej Jakubowiak, Owen A. O’Connor, Robert Z. Orlowski, R. Donald Harvey, Mitchell R. Smith, Daniel Lebovic, Catherine Diefenbach, Kevin R. Kelly, Zhaowei Hua, Allison Berger, George Mulligan, Hélène M. Faessel, Stephen Tirrell, Bruce J. Dezube, Sagar Lonial	162
8	Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma 2015 ·Clinical Cancer Research ·Jennifer E. Amengual, Paul Johannet, Maximilian Lombardo, Kelly Zullo, Daniela Hoehn, Govind Bhagat, Luigi Scotto, (unknown), Dejan Radeski, (unknown), Hongfeng Jiang, Serge Cremers, Yuan Zhang, Simon Jones, Owen A. O’Connor	71
9	Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma 2015 ·Clinical Cancer Research ·Kelly Zullo, (unknown), Laurence Cooke, (unknown), (unknown), Luigi Scotto, Jennifer E. Amengual, Yinghui Mao, Renu Nandakumar, Serge Cremers, Jimmy Duong, Daruka Mahadevan, Owen A. O’Connor	33
10	Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma 2015 ·Blood ·Ann S. LaCasce, Gregory Bociek, Ahmed Sawas, Paolo F. Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas‐Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero‐Torres, Julie M. Vose, Owen A. O’Connor, Neil C. Josephson, Ranjana H. Advani	43
11	The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-κB 2014 ·Clinical Cancer Research ·Changchun Deng, (unknown), Richard Rodríguez, (unknown), Christine McIntosh, Wei‐Yann Tsai, (unknown), Susan Jaken, Owen A. O’Connor	21
12	Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas 2012 ·Clinical Cancer Research ·Luigi Scotto, Marianna Kruithof‐de Julio, Luca Paoluzzi, Matko Kalac, Enrica Marchi, (unknown), Jennifer E. Amengual, Michael M. Shen, Owen A. O’Connor	10
13	A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma 2012 ·Clinical Cancer Research ·Melissa Alsina, Suzanne Trudel, Richard R. Furman, Peter J. Rosen, Owen A. O’Connor, Raymond L. Comenzo, Alvin Wong, Lori Kunkel, Christopher J. Molineaux, André Goy	119
14	Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study breakdown → 2011 ·Journal of Clinical Oncology ·Owen A. O’Connor, Barbara Pro, Lauren Pinter‐Brown, Nancy L. Bartlett, Leslie Popplewell, Bertrand Coiffier, Mary Jo Lechowicz, Kerry J. Savage, Andrei R. Shustov, Christian Gisselbrecht, Eric D. Jacobsen, Pier Luigi Zinzani, Richard R. Furman, André Goy, Corinne Haïoun, Michael Crump, Jasmine Zain, Eric D. Hsi, Adam P. Boyd, Steven M. Horwitz	439
15	Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma 2010 ·Clinical Cancer Research ·Luca Paoluzzi, Luigi Scotto, Enrica Marchi, Jasmine Zain, Venkatraman Seshan, Owen A. O’Connor	58
16	Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies 2010 ·Clinical Cancer Research ·Enrica Marchi, Luca Paoluzzi, Luigi Scotto, Venkatraman Seshan, Jasmine Zain, Pier Luigi Zinzani, Owen A. O’Connor	52
17	Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma 2010 ·Journal of Clinical Oncology ·Craig H. Moskowitz, Heiko Schöder, Julie Teruya‐Feldstein, Camelia S. Sima, Alexia Iasonos, Carol S. Portlock, David J. Straus, Ariela Noy, Maria Lia Palomba, Owen A. O’Connor, Steven M. Horwitz, Sarah A. Weaver, (unknown), Daniel A. Filippa, James F. Caravelli, Paul A. Hamlin, Andrew D. Zelenetz	225
18	Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies 2009 ·Journal of Clinical Oncology ·Owen A. O’Connor, Steven M. Horwitz, Paul A. Hamlin, Carol S. Portlock, Craig H. Moskowitz, Debra Sarasohn, Ellen Neylon, (unknown), (unknown), Barbara MacGregor‐Cortelli, Molly Bruce Patterson, Venkatraman Seshan, (unknown), Martin Fleisher, Diane R. Mould, M.I. Saunders, Andrew D. Zelenetz	131
19	Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs 2008 ·Cancer Research ·Mark Heaney, Jeffrey R. Gardner, Nicos Karasavvas, David W. Golde, David A. Scheinberg, Emily A. Smith, Owen A. O’Connor	169
20	Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies 2005 ·Journal of Clinical Oncology ·Owen A. O’Connor, Mark Heaney, Lawrence B. Schwartz, (unknown), (unknown), Barbara MacGregor‐Cortelli, (unknown), Craig H. Moskowitz, Carol S. Portlock, Steven M. Horwitz, Andrew D. Zelenetz, Stanley Frankel, Victoria M. Richon, Paul A. Marks, William Kevin Kelly	345

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact